Business
Altimmune Announces Third Quarter 2021 Financial Results and Provides a Corporate Update
Exploratory MRI-PDFF analysis of subjects with hepatic steatosis in recently completed Phase 1 study of pemvidutide shows reduction of liver fat to
About this update from Altimmune, Inc.
[{"type":"text","content":"Exploratory MRI-PDFF analysis of subjects with hepatic steatosis in recently completed Phase 1 study of pemvidutide shows reduction of liver fat to undetectable levels after 6 weeks of treatment Approximately $200 Million in cash and short-term investments to advance pipeline GAITHERSBURG, Md., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three- and nine-months ending September 30, 2021 and provided a corporate update. “The third quarter was a momentous time for our pemvidutide (ALT-801) program, as we delivered on positive topline data for the 12-week Phase 1 trial, cleared an IND in non-alcoholic steatohepatitis (NASH) with the FDA and initiated a 12-week Phase 1b study in non-alcoholic fatty liver disease (NAFLD),” remarked Vipin K. Garg, Ph.D., President and Chief Executive Officer at Altimmune. “In addition to the previously announced 12-week data showing double-digit weight loss in the 1.8 mg arm without the need for dose titration, we now have MRI-PDFF data in a subset of subjects with hepatic steatosis, or fatty liver, from that study demonstrating a remarkable reduction in liver fat to undetectable levels after only 6 weeks of pemvidutide treatment. These findings show the potential of pemvidutide in the treatment of both obesity and NASH, and we look forward to sharing the data from our ongoing Phase 1b trial in NAFLD and initiating Phase 2 trials for obesity and NASH in 2022.” Program Highlights: Pemvidutide1 (ALT-801) Announced weight loss data from 12-week Phase 1 clinical trial of pemvidutide in overweight and obese subjects Subjects achieved mean weight losses of 4.9%, 10.3%, and 9.0% at 1.2 mg, 1.8 mg, and 2.4 mg doses, respectivelyOnce-weekly dosing regimen was well-tolerated without dose titrationClinically meaningful reductions in serum lipids and blood pressureNo discontinuations due to adverse events Obesity program advancing towards 48-week Phase 2 trial in the first half of 2022 Investigational New Drug application (IND) for obesity expected to be submitted by year end 202148-week Phase 2 obesity study expected to commence in the first half of 2022 1 proposed INN Reduction in liver fat by MRI-PDFF exploratory analysis in recently completed Phase 1 study MRI-PDFF data on liver fat content have now been ...